Firstsource Solutions (FIRSOU)

CMP: ₹ 299

Target: ₹ 360 (20.4%)

Target Period: 12 months

August 1, 2024



BUY

ICICI direct



Particulars	
Particular	Amount
Market Cap (₹ Crore)	20,344.0
Total Debt (₹ Crore)	812.3
Cash (₹ Crore)	218.5
EV (₹ Crore)	20,937.9
52 week H/L	309/140
Equity capital	697.0
Face value	10.0

Shareholding pattern								
	Sep-23	Dec-23	Mar-24	Jun-24				
Promoters	54	54	54	54				
FII	10	10	10	9				
DII	16	18	19	20				
Other	20	18	17	17				

250 210 - 27 - 27 - 2000 170 - 130 - 27 - 27 - 2000 130 - 27 - 27 - 2000 10 - 27 - 27 - 2000 10 - 27 - 27 - 2000 10 - 27 - 2000 10 - 27 - 2000 10 - 27 - 2000 10 - 2000

Key risks

Price Chart

 Delay in interest rate cut in US, impacting the mortgage business;

- Nifty (RHS)

Firstsource (LHS) -

• Lower than expected margin growth

Research Analyst

Bhupendra Tiwary, CFA bhupendra.tiwary@icicisecurities.com

CA Anjini Sharma anjini.sharma@icicisecurities.com

Strong guarter, poised for a healthy growth ahead...

About the stock: Firstsource Solutions (FSL) provides business process services to BFSI, communication, media, tech and healthcare.

- The company generates ~68% revenues from the US and 32% from the UK
- FSL is a domain driven BPM services company which has 200+ global clients, including 19 Fortune 500 companies & 3 FTSE 100 companies. It has 29,231 employees across US, UK, India, Philippines, South Africa etc.

Q1FY25 Performance: FSL reported its highest ever quarterly revenue of ₹1,783.87 cr, up 6.9% QoQ/16.8% YoY. In US\$ terms revenue came at US\$ 215 mn, up 6.7% QoQ/15.4% YoY (6.5% QoQ/14.8% YoY in CC terms – including 2% contribution from QBSS acquisition). EBIT margin was at 11%, flat QoQ. FSL won 3 large deals and added 10 new logos.

Investment Rationale:

- Sustained revenue & margin growth momentum: Based on the strong revenue growth in Q1, the company revised its revenue growth guidance to 11.5-13.5% in CC terms (vs.10-13% earlier). FSL maintained its EBIT margin guidance in the range of 11-12% for FY25 & expansion of 50-75 bps each year thereafter over the medium term. The upward revision seems a little conservative considering the healthy growth witnessed in Q1 & the strong deal pipeline. We expect it to beat this revenue & margin guidance. Further FSL reiterated its target to achieve US\$ 1 billion exit revenue run rate by FY26. With improved revenue visibility over the medium term, we have introduced our FY27E estimates & accordingly baked in 14.9% CAGR in revenues over FY24-27E to US\$ 1,160 mn.
- Key margins levers over the medium term: The management has identified 24 margin levers such as offshoring/rightshoring, increasing span of control and consolidation of onsite delivery locations. These efforts would ultimately converge margins in the range of 14-15% over the next 3-4 years. Accordingly, we have baked in EBIT margins of 11.5%, 12.3% and 13.1% for FY25/FY26/27E. Healthy revenue growth coupled with margins expansion to drive ~24.7% earnings CAGR over FY24-27E.
- Broad-based deal & client wins: FSL won 3 large deals and added 10 new logos in this quarter. FSL has reduced its macro-dependency on its BFS vertical and now looks forward to a more broad-based growth across Healthcare. CMT and Diverse verticals.

Rating and Target Price

- FSL is well placed to sustain its medium and long-term growth momentum driven by client acquisition, structural changes, GenAl and margin enhancement initiatives.
- We rollover our estimates and maintain BUY, with a target price of ₹360; at 28x P/E on average of FY26E & FY27E EPS.

Key Financial Summary 5 year CAGR 3 year CAGR ₹ crore FY22 FY23 FY24 FY25E FY26E FY27E (FY19-24) (FY24-27E) 7,255 **Net Sales** 5,921 6,022 8,436 9,765 6.336 10.6% 15.5% **EBITDA** 960 827 956 12.3% 1,130 1,373 1,660 20.2% **EBITDA Margins (%)** 16.2 13.7 15.1 15.6 16.3 17.0 **Net Profit** 537 514 515 6.4% 601 790 997 24.7% EPS (₹) 7.6 7.3 7.3 8.6 11.3 14.2 P/E 37.8 39.6 39.5 33.9 25.8 20.4 RoNW (%) 17.7 15.3 13.9 15.0 17.8 20.0 RoCE (%) 14.5 14.5 14.0 15.3 18.3 21.3

Performance highlights and outlook

- Revenue Performance: FSL reported a revenue of ₹1,783.87 cr, up 6.9% QoQ/16.8% YoY. In dollar terms it reported a revenue of US\$ 215 mn, up 6.7% QoQ/15.4% YoY (6.5% QoQ/14.8% YoY in CC terms including 2% contribution from QBSS acquisition).
- Geography performance: Geography wise on a QoQ basis, growth was led by North America (68.2% of mix) which grew by 12.2% while Europe & MEA (31.8% of mix) and ROW (0% of mix) declined by 2.5% and 100% respectively.
- Vertical wise Performance and outlook: Vertical wise Healthcare (35.7% of mix), BFS (36.4% of mix) and CMT (22.3% of mix) reported growth of 16.1%, 4.4% & 1.1% QoQ respectively while Others (5.6% of mix) declined by 3.4% QoQ.
 - BFS vertical: The segment grew both sequentially and on a YoY basis in CC terms despite Q1 being a seasonally muted quarter. FSL reduced its macro dependency on the segment with increased focus on cost optimisation programs which have helped it in increasing its market share. Elevated interest rates continue to remain an overhang in the mortgage market. Additionally, the company's Al use case for this segment is also seeing strong interest from its clients. The management expects a sequentially improving growth trajectory in this segment for the rest of FY25 with 5 new logos being added in the segment for Q1.
 - Healthcare vertical: Q1 was a strong quarter for the healthcare vertical, aided by the ramp up in the deals won in the recent quarters, especially in the payer segment. It won 2 large deals in the segment during the quarter.
 - <u>CMT Segment:</u> The company is seeing a healthy momentum in the telecom and media business. Overall, 3 new logos were added in this segment. The offshoring of their top client might pose as a headwind in the short term. However, the segment is expected to see steady growth moving forward.
- Margin performance and Outlook: FSL in Q4 reported an EBIT margin of 11%, flat QoQ while PAT stood at ₹135.3 crore, up 1.3% QoQ/ 7.4% YoY and PAT margin came at 7.6% (down 40 bps QoQ). The management mentioned having identified 24 margin levers such as offshoring/rightshoring, increasing span of control and consolidation of onsite delivery locations. These efforts would ultimately converge margins in the range of 14-15% over the next 3-4 years. However, for FY25 it would continue to operate within a band of 11-12%. Additionally, accounts with suboptimal profitability are identified and corrective steps are being take for the same.
- GenAl/Al: The company is making significant investments in the GenAl space. During the quarter, it launched "RelAl" suite of Al led solutions and platforms to drive transformation of clients in a responsible manner. FSL's other GenAl capabilities include Firstsense.Al, FirstCollab, and Partner ecosystem. Further, it has completed 55+ POCs while 8+ co-pilots are in production.
- Deal Wins: FSL won 3 large deals and added 10 new logos during the quarter. Noteworthy wins include one of the top 5 Banks in the UK and additional business from existing clients in retail banking and healthcare.
- Attrition & Employee addition: During Q1 FSL added 1,291 new employees bringing the total employee strength to 29,231 employees. The TTM attrition rate further declined to 32%.

Exhibit 1: Quarter Perform	ance					
₹ crore	Q1FY25	Q1FY24	YoY (%)	Q4FY24	QoQ (%)	Comments
Revenue	1,791.1	1,529.2	17.1	1,670.5	7.2	Revenue grew by 6.5% QoQ in CC terms & 6.7% in dollar terms
Employee expenses	1,126.8	923.7	24.2	1,055.8	7.4	
Gross Margin	664.3	605.5	9.7	614.7	8.1	
Gross margin (%)	37.1	39.6	-250 bps	36.8	29 bps	
SG&A expenses	394.4	365.3	8.0	364.3	8.3	
EBITDA	269.9	240.2	12.4	250.3	7.8	
EBITDA Margin (%)	15.1	15.7	-64 bps	15.0	8 bps	
Depreciation & amortisation	72.9	61.3	18.9	67.3	8.2	
EBIT	197.0	178.9	10.1	183.0	7.7	
EBIT Margin (%)	11.0	11.7	-70 bps	11.0	4 bps	Margins continue to improve due cost optimisation and operational efficiencies
Other income (less interest)	-29.8	-23.6	25.9	-23.7	25.5	
PBT	167.3	155.3	7.7	159.3	5.0	
Tax paid	32.0	29.3	9.2	25.8	24.1	
PAT	135.3	126.0	7.4	133.5	1.3	

Source: Company, ICICI Direct Research

Financial Summary

Exhibit 2: Profit and I	oss state	ment			₹ crore
(Year-end March)	FY23	FY24	FY25E	FY26E	FY27E
Total Revenues	6,022	6,336	7,255	8,436	9,765
Growth (%)	1.7	5.2	14.5	16.3	15.8
Employee expenses	3,867	3,909	4,532	5,230	6,006
Other Expenses	1,328	1,471	1,593	1,832	2,099
EBITDA	827	956	1,130	1,373	1,660
Growth (%)	(13.9)	15.7	18.1	21.6	20.9
Depreciation & Amortization	263	260	297	337	381
Other Income	131	37	15	23	32
Interest	79	103	107	84	80
PBT before Exceptional Items	615	630	742	975	1,231
Growth (%)	(4.9)	2.4	17.8	31.5	26.3
Tax	102	115	141	185	234
PAT before Excp Items	514	515	601	790	997
Exceptional items					
PAT before MI	514	515	601	790	997
Minority Int & Pft. from asso.	0	(0)	(0)	-	-
PAT	514	515	601	790	997
Growth (%)	(4.4)	0.2	16.7	31.5	26.3
EPS	7.3	7.3	8.6	11.3	14.2
EPS (Growth %)	(3.8)	0.2	16.7	31.5	26.3

Exhibit 3: Cash flow sto	atement			₹ cro	re
(Year-end March)	FY23	FY24	FY25E	FY26E	FY27E
Profit before Tax	615	630	742	975	1,231
Dep & Amortization	263	260	297	337	381
WC changes	76	(240)	(123)	(160)	(180)
Other non cash adju.	(160)	(5)	(50)	(124)	(186
CF from operations	795	645	865	1,029	1,247
Capital expenditure	(54)	(85)	(217)	(84)	(97
Δ in investments	64	36	-	-	-
Other investing cash flow	1	1	15	23	32
CF from Inv Activities	16	(58)	(202)	(61)	(65)
Issue of equity	(42)	(52)	-	-	-
Δ in debt funds	(198)	128	-	(200)	(200
Dividends paid	(238)	(241)	(288)	(355)	(449)
Other financing cash flow	(79)	(101)	(107)	(84)	(80)
CF from Fin Activities	(743)	(564)	(488)	(732)	(822)
Δ in cash and cash bank	68	23	176	235	359
Effect of exchange rate changes	•				
Opening cash	90	156	188	364	599
Closing cash	156	188	364	599	958

Source: Company, ICICI Direct Research

Exhibit 4: Balance S	heet				₹ crore
(Year-end March)	FY23	FY24	FY25E	FY26E	FY27E
Equity	697	697	697	697	697
Reserves & Surplus	2,670	3,003	3,316	3,750	4,299
Networth	3,367	3,700	4,013	4,447	4,996
Minority Interest	0	0	0	0	0
LT liabilties & provisions	598	737	737	737	737
Total Debt	827	812	812	612	412
Source of funds	4,792	5,250	5,563	5,797	6,145
Net fixed assets	670	800	813	653	462
CWIP	3	17	17	17	17
Goodwill	2,945	2,988	2,988	2,988	2,988
Other non current assets	638	740	794	863	941
Loans and advances	-	-	-	-	-
Current Investments	60	30	30	30	30
Debtors	1,038	1,161	1,327	1,543	1,786
Cash & Cash equivalents	156	188	364	599	958
Other current assets	155	158	181	210	243
Trade payables	231	306	349	406	470
Current liabilities	558	460	526	612	708
Provisions	83	67	77	89	103
Application of funds	4,792	5,250	5,563	5,797	6,145

Source: Company,	ICICI	Direct Research
------------------	-------	-----------------

Exhibit 5: Key ratios					
(Year-end March)	FY23	FY24	FY25E	FY26E	FY27E
Per share data (₹)					
EPS-diluted	7.3	7.3	8.6	11.3	14.2
DPS	3.5	3.5	4.1	5.0	-
BV	49.5	54.4	59.0	65.4	73.4
Operating Ratios (%)					
EBITDA Margin	13.7	15.1	15.6	16.3	17.0
PBT Margin	10.2	9.9	10.2	11.6	12.6
PAT Margin	8.5	8.1	8.3	9.4	10.2
Return Ratios (%)					
RoNW	15.3	13.9	15.0	17.8	20.0
RoCE	14.5	14.0	15.3	18.3	21.3
Valuation Ratios (x)					
P/E	39.6	39.5	33.9	25.8	20.4
EV / EBITDA	25.4	21.9	18.4	14.8	11.9
Price to Book Value	6.0	5.5	5.1	4.6	4.1
EV / Net Sales	3.5	3.3	2.9	2.4	2.0
Mcap / Net Sales	3.4	3.2	2.8	2.4	2.1
Turnover Ratios					
Debtor days	63	67	67	67	67
Creditors days	14	18	18	18	18
Solvency Ratios					
Total Debt / Equity	0.2	0.2	0.2	0.1	0.1
Current Ratio	1.4	1.6	1.6	1.6	1.6
Quick Ratio	1.4	1.6	1.6	1.6	1.6
Net Debt / EBITDA	0.7	0.6	0.4	(0.0)	(0.3)

Source: Company, ICICI Direct Research



RATING RATIONALE

ICICI Direct endeavours to provide objective opinions and recommendations. ICICI Direct assigns ratings to its stocks according to their notional target price vs. current market price and then categorizes them as Buy, Hold, Reduce and Sell. The performance horizon is two years unless specified and the notional target price is defined as the analysts' valuation for a stock

Buy: >15%

Hold: -5% to 15%;

Reduce: -15% to -5%;

Sell: <-15%



Pankaj Pandey

Head - Research

pankaj.pandey@icicisecurities.com

ICICI Direct Research Desk, ICICI Securities Limited, Third Floor, Brillanto House, Road No 13, MIDC, Andheri (East) Mumbai – 400 093 research@icicidirect.com

ANALYST CERTIFICATION

I/We, Bhupendra Tiwary, CFA, MBA (Finance), Anjini Sharma, CA, Research Analysts Research Analysts, authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect our views about the subject issuer(s) or securities. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report. It is also confirmed that above mentioned Analysts of this report have not received any compensation from the companies mentioned in the report in the preceding twelve months and do not serve as an officer, director or employee of the companies mentioned in the report.

Terms & conditions and other disclosures:

ICICI Securities Limited (ICICI Securities) is a full-service, integrated investment banking and is, inter alia, engaged in the business of stock brokering and distribution of financial products.

ICICI Securities is Sebi registered stock broker, merchant banker, investment adviser, portfolio manager and Research Analyst. ICICI Securities is registered with Insurance Regulatory Development Authority of India Limited (IRDAI) as a composite corporate agent and with PFRDA as a Point of Presence. ICICI Securities Limited Research Analyst SEBI Registration Number – INH00000990. ICICI Securities Limited SEBI Registration is INZ000183631 for stock broker. Registered Office Address: ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025. CIN: L67120MH1995PLC086241, Tel: (91 22) 6807 7100. ICICI Securities is a subsidiary of ICICI Bank which is India's largest private sector bank and has its various subsidiaries engaged in businesses of housing finance, asset management, life insurance, general insurance, venture capital fund management, etc. ("associates"), the details in respect of which are available on www.icicibank.com.

Investments in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by Sebi and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors. None of the research recommendations promise or guarantee any assured, minimum or risk-free return to the investors.

Name of the Compliance officer (Research Analyst): Mr. Atul Agrawal

Contact number: 022-40701000 E-mail Address: complianceofficer@icicisecurities.com

For any queries or grievances: Mr. Bhavesh Soni Email address: headservicequality@icicidirect.com Contact Number: 18601231122

ICICI Securities is one of the leading merchant bankers/ underwriters of securities and participate in virtually all securities trading markets in India. We and our associates might have investment banking and other business relationship with a significant percentage of companies covered by our Investment Research Department. ICICI Securities and its analysts, persons reporting to analysts and their relatives are generally prohibited from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover.

Recommendation in reports based on technical and derivative analysis centre on studying charts of a stock's price movement, outstanding positions, trading volume etc as opposed to focusing on a company's fundamentals and, as such, may not match with the recommendation in fundamental reports. Investors may visit icicidirect.com to view the Fundamental and Technical Research Reports.

Our proprietary trading and investment businesses may make investment decisions that are inconsistent with the recommendations expressed herein.

ICICI Securities Limited has two independent equity research groups: Institutional Research and Retail Research. This report has been prepared by the Retail Research. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the Institutional Research.

The information and opinions in this report have been prepared by ICICI Securities and are subject to change without any notice. The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of ICICI Securities. While we would endeavour to update the information herein on a reasonable basis, ICICI Securities is under no obligation to update or keep the information current. Also, there may be regulatory, compliance or other reasons that may prevent ICICI Securities from doing so. Non-rated securities indicate that rating on a particular security has been suspended temporarily and such suspension is in compliance with applicable regulations and/or ICICI Securities policies, in circumstances where ICICI Securities might be acting in an advisory capacity to this company, or in certain other circumstances.

This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. ICICI Securities will not treat receipients as customers by virtue of their receiving this report. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. The recipient should independently evaluate the investment risks. The value and return on investment may vary because of changes in interest rates, foreign exchange rates or any other reason. ICICI Securities accepts no liabilities whatsoever for any loss or damage of any kind arising out of the use of this report. Past performance is not necessarily a guide to future performance. Investors are advised to see Risk Disclosure Document to understand the risks associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice.

ICICI Securities or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months.

ICICI Securities or its associates might have received any compensation from the companies mentioned in the report during the period preceding twelve months from the date of this report for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory service in a merger or specific transaction.

ICICI Securities or its associates might have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the companies mentioned in the report in the past twelve months.

ICICI Securities encourages independence in research report preparation and strives to minimize conflict in preparation of research report. ICICI Securities or its associates or its analysts did not receive any compensation or other benefits from the companies mentioned in the report or third party in connection with preparation of the research report. Accordingly, neither ICICI Securities nor Research Analysts and their relatives have any material conflict of interest at the time of publication of this report.

Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions.

ICICI Securities or its subsidiaries collectively or Research Analysts or their relatives do not own 1% or more of the equity securities of the Company mentioned in the report as of the last day of the month preceding the publication of the research report.

Since associates of ICICI Securities and ICICI Securities as a entity are engaged in various financial service businesses, they might have financial interests or actual/beneficial ownership of one percent or more or other material conflict of interest various companies including the subject company/companies mentioned in this report.

ICICI Securities may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report.